Cagrilintide vs GLP-3 RTA
Cagrilintide and GLP-3 RTA are both studied in weight research, but they are different classes of compound with different reported research applications.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do Cagrilintide and GLP-3 RTA differ?
Cagrilintide (Long-acting amylin analog peptide) is catalogued under weight & metabolic research; GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research. Verve lists 5 reported research applications for Cagrilintide and 5 for GLP-3 RTA. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | Cagrilintide | GLP-3 RTA |
|---|---|---|
| compound class | Long-acting amylin analog peptide | Synthetic triple-agonist peptide |
| research area | weight & metabolic | weight & metabolic |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | single compound |
| catalog sizes | 10mg | 10mg · 20mg · 30mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | not offered | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $157.49 | $142.99 |
| availability | out of stock | in stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is Cagrilintide and what is GLP-3 RTA?
Cagrilintide is classified as Long-acting amylin analog peptide; GLP-3 RTA as Synthetic triple-agonist peptide. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
Cagrilintide
Long-acting amylin analog peptide
Cagrilintide is a synthetic long-acting analog of amylin, the pancreatic peptide co-secreted with insulin from beta cells. Its sequence is engineered for solubility and resistance to aggregation, and it carries a fatty-acid side chain that extends circulating half-life in pre-clinical systems, giving researchers a stable tool compound where native amylin is notoriously difficult to work with.
full Cagrilintide profile →GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →Which research models is each compound studied in?
Cagrilintide and GLP-3 RTA both sit inside weight & metabolic research, so their listed models share framing while differing in specifics. The table lists 5 reported research applications for Cagrilintide and 5 for GLP-3 RTA. Rows are per compound, not equivalences.
| Cagrilintide — reported research applications | GLP-3 RTA — reported research applications |
|---|---|
| Amylin- and calcitonin-receptor agonism research | GLP-1, GIP, and glucagon receptor agonism research |
| Calcitonin-receptor / RAMP complex pharmacology studies | cAMP and class B GPCR signaling research models |
| Peptide aggregation, solubility, and stability research | Comparative single-, dual-, and triple-agonist pharmacology studies |
| Metabolic-signaling research models | Metabolic-pathway and nutrient-handling research models |
| Comparative studies alongside incretin-receptor reference compounds | Peptide half-life, lipidation, and stability research |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for Cagrilintide and GLP-3 RTA?
Cagrilintide is listed from $157.49 and GLP-3 RTA from $142.99. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| Cagrilintide | 10mg | $157.49 | out of stock |
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about Cagrilintide and GLP-3 RTA
What is Cagrilintide?
Cagrilintide is a synthetic long-acting analog of the pancreatic peptide amylin, engineered for stability and extended half-life. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is Cagrilintide studied for in research?
It is used as a reference agonist in amylin- and calcitonin-receptor pharmacology, RAMP-complex research, and metabolic-signaling models in vitro and pre-clinically. Verve makes no health claims.
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.